Oncotelic Therapeutics
↗Agoura Hills, California, USA
Oncotelic Therapeutics is an immuno-oncology company dedicated to developing first-in-class RNA therapeutics and small molecule drugs for the treatment of cancer and rare diseases. The company leverages its proprietary anti-TGF-β antisense platform technology that has demonstrated the ability to break immune tolerance and enhance anti-tumor immunity. Oncotelic combines its clinical-stage pipeline with advanced manufacturing capabilities through a joint venture with GMP Biotechnology, developing nanoparticle-based therapeutics (Deciparticle™) targeting late-stage oncology indications including pancreatic cancer, glioblastoma, melanoma, and rare pediatric cancers. The company was originally founded as OXiGENE, Inc. in 1988, became Mateon Therapeutics in 2016, and adopted its current name following the 2019 merger with Oncotelic Inc.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Immuno-oncology, RNA therapeutics
SIZE & FINANCIALS
Employees:11-50
Revenue:$0-$100K
Founded:1988
Ownership:public
Status:operating
FUNDING
Stage:Public/Commercial
Total Raised:$10.1M
Investors:Dragon Capital Overseas Limited (45% of GMP BioTech JV)
STOCK
Exchange:OTC Markets (OTCQB)
Ticker:OTLC
Market Cap:$41.2M
PIPELINE
Stage:Phase 1|Phase 2|Phase 3
Lead Drug Stage:Phase 2b/3
Modalities:Antisense RNA, Small molecule, Vascular disrupting agents, Nanoparticles
Active Trials:6
Trial Phases:Phase 1: 2 | Phase 2: 3 | Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:GMP Biotechnology Limited (45% ownership), Dragon Capital Overseas Limited (55%), Edgepoint (formed February 2020)
Key Partnerships:Shanghai Medicilon - Rapid IND development platform for up to 20 cancer drug programs, GMP Biotechnology Limited - Joint venture for GMP manufacturing and nanoparticle platform (Deciparticle™), Nebraska Medicine - Phase I/II trial collaboration for OT-101 with pembrolizumab
COMPETITION
Position:Emerging|Niche Player
Competitors:Eli Lilly (galunisertib - TGF-β kinase inhibitor), MedPacto (vactosertib - TGF-β inhibitor), Rgenix (SHR-1701 - anti-PD-L1/TGF-βRII fusion protein), Transgene (NIS793 - TGF-β inhibitor), Acceleron/Merck (sotatercept - ActRIIA ligand trap)
LEADERSHIP
Key Executives:
Dr. Vuong Trieu - Co-Founder, Chairman & CEO
Anthony Maida III - Chief Clinical Officer - Translational Medicine
Matthew M. Loar - Chief Financial Officer
Scientific Founders:Dr. Vuong Trieu (Co-Founder)
Board Members:Dr. Vuong Trieu (Chairman & CEO), William D. Schwieterman (President, former CEO of Mateon), Dr. David Horwitz (Medical Advisory Board - Professor of Medicine and Molecular Immunology, USC Keck School of Medicine, T-cell biology specialist), Dr. Reinhard von Roemeling (Medical Advisory Board - Medical oncologist, Fox Chase Comprehensive Cancer Center)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Oncotelic Therapeutics. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.